Bronchiolitis Obliterans - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 42

Bronchiolitis Obliterans – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Bronchiolitis Obliterans - Pipeline Review, H1 2012', provides an overview of the Bronchiolitis Obliterans therapeutic pipeline. This report provides information on the therapeutic development for Bronchiolitis Obliterans, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiolitis Obliterans. 'Bronchiolitis Obliterans - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchiolitis Obliterans.
- A review of the Bronchiolitis Obliterans products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchiolitis Obliterans pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchiolitis Obliterans.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchiolitis Obliterans pipeline depth and focus of Bronchiolitis Obliterans therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bronchiolitis Obliterans Therapeutic Products under Development, Key Players in Bronchiolitis Obliterans Therapeutics, Bronchiolitis Obliterans Pipeline Overview, Bronchiolitis Obliterans Pipeline, Bronchiolitis Obliterans Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchiolitis Obliterans Overview
Therapeutics Development
An Overview of Pipeline Products for Bronchiolitis Obliterans
Bronchiolitis Obliterans Therapeutics under Development by Companies
Bronchiolitis Obliterans Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Bronchiolitis Obliterans Therapeutics – Products under Development by Companies
Bronchiolitis Obliterans Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bronchiolitis Obliterans Therapeutics Development
PARI Pharma GmbH
Pacific Therapeutics Ltd.
Bronchiolitis Obliterans – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PTL-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Symbicort - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporine + Hematopoietic Stem Cell Transplantation + Propylene Glycol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Formoterol + Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-CsA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluticasone Propionate + Azithromycin + Montelukast Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bronchiolitis Obliterans Therapeutics – Drug Profile Updates
Bronchiolitis Obliterans Therapeutics - Dormant Products
Bronchiolitis Obliterans – Product Development Milestones
Featured News & Press Releases
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bronchiolitis Obliterans, H1 2012
Products under Development for Bronchiolitis Obliterans – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
PARI Pharma GmbH, H1 2012
Pacific Therapeutics Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bronchiolitis Obliterans Therapeutics – Drug Profile Updates
Bronchiolitis Obliterans Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Bronchiolitis Obliterans, H1 2012
Products under Development for Bronchiolitis Obliterans – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Bronchiolitis Obliterans - Pipeline Review, H2 2012
• Bronchiolitis Obliterans - Pipeline Review, H2 2011
• Bronchiolitis - Pipeline Review, H2 2012
• Bronchiolitis Obliterans - Pipeline Review, Q2 2011
• Bronchiolitis - Pipeline Review, H1 2012
• Bronchiolitis - Pipeline Review, H2 2011
• Respiratory Tract Inflammatory Disorders - Pipeline Review, H1 2013
• Bronchitis - Pipeline Review, H2 2012
• Bronchiolitis - Pipeline Review, Q2 2011
• Bronchitis - Pipeline Review, H1 2012